Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 12, 2001, Pages 1629-1636

  Sukbuntherng, Juthamas ^a   Cropp, Gillian ^a   Hannah, Alison ^a   Wagner, Gregory S ^b   Shawver, Laura K ^a   Antonian, Lida ^a  

^a SUGEN INC   (United States)

^b RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CREMOPHOR; SEMAXANIB; VASCULOTROPIN INHIBITOR;

ALLOMETRY; ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MAJOR CLINICAL STUDY; MALE; MONKEY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PREDICTION; RAT; RODENT; SPECIES DIFFERENCE; STEADY STATE;

ANGIOGENESIS INHIBITORS; ANIMALS; DOGS; FEMALE; HUMANS; INDOLES; MALE; METABOLIC CLEARANCE RATE; MICE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SPECIES SPECIFICITY;

EID: 0035678986     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011778232     Document Type: Article

References (17)

1. Biotransformation of an anti-angiogenic compound SU5416
2. Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients
3. Pharmacokinetics and pharmacodynamics of SU5416 in a Phase I, dose-escalating trial in patients with advanced malignancies
4. Physiological parameters in laboratory animals and humans
5. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
6. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices
7. Interspecies scaling of Bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling
8. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor
9. Interspecies scaling of renally secreted drugs
10. Development of SU5416. A selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
11. The use of interspecies scaling in toxicokinetics
12. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
13. Receptor tyrosine kinases as target for inhibition of angiogenesis
14. Flk-1 as a target for tumor growth inhibition
15. Pharmacokinetics in drug discovery and development: Nonclinical studies
16. Inhibition of tumor growth, angiogenesis, and micro-circulation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
17. Dependence of pharmacokinetic parameters on body weight